Oruka Therapeutics (NASDAQ:ORKA) CEO Sells $2,090,500.00 in Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) CEO Lawrence Klein sold 25,000 shares of the firm’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $83.62, for a total value of $2,090,500.00. Following the completion of the transaction, the chief executive officer owned 923,128 shares in the company, valued at approximately $77,191,963.36. This trade represents a 2.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Lawrence Otto Klein also recently made the following trade(s):

• On Tuesday, September 15th, Lawrence Klein sold 2,452 shares of Oruka Therapeutics stock. The shares were sold at an average price of $95.71, for a total value of $234,680.92.
• On Tuesday, September 1st, Lawrence Klein sold 75,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $91.83, for a total value of $6,887,250.00.

Oruka Therapeutics Stock Performance

ORKA stock opened at $84.52 on Monday. Oruka Therapeutics, Inc. has a fifty-two week low of $19.04 and a fifty-two week high of $115.51. The business’s 50-day moving average is $95.77 and its two-hundred day moving average is $77.71. The company has a market cap of $5.60 billion, a price-to-earnings ratio of -41.64 and a beta of -0.37.

Oruka Therapeutics (NASDAQ:ORKA) last announced its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). Equities analysts predict that Oruka Therapeutics, Inc. will post -2.42 earnings per share for the current year.

Institutional Investors Weigh In On Oruka Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Nykredit A S purchased a new position in Oruka Therapeutics during the second quarter valued at approximately $29,000. Orion Capital Management LLC purchased a new stake in shares of Oruka Therapeutics in the second quarter worth $91,000. Natural Investments LLC purchased a new stake in shares of Oruka Therapeutics in the second quarter worth $202,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Oruka Therapeutics during the 4th quarter valued at $67,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Oruka Therapeutics during the 2nd quarter valued at $211,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ORKA has been the subject of several recent research reports. HC Wainwright restated a “buy” rating and set a $120.00 target price on shares of Oruka Therapeutics in a research report on Thursday, September 24th. Weiss Ratings upgraded shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. UBS Group lifted their price target on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. BTIG Research restated a “buy” rating and issued a $151.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Finally, Wedbush set a $120.00 price objective on Oruka Therapeutics in a research note on Thursday, September 24th. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $128.91.

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company’s approach is designed to extend the duration of treatment and potentially reduce the frequency of dosing for patients with chronic inflammatory conditions.

Oruka’s pipeline includes ORKA-001 and ORKA-002, next-generation monoclonal antibodies targeting interleukin-23 (IL-23), a cytokine involved in several autoimmune and inflammatory diseases.